2016-11-14T14:52:00-06:00 2015-12-31 560747981 DIXON HUGHES GOODMAN LLP 901 EAST CARY STREET SUITE 1000 RICHMOND VA 23219 990 2015-01-01 521986675 FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC FOUN 3014025311 9650 ROCKVILLE PIKE NO 3411 BETHESDA MD 20814 MARIA FREIRE PHD PRESIDENT 3014025311 2016-11-14 1 LORI K COCHRAN P00853221 8042827636 2015 2017-02-10 21:41:12Z MARIA FREIRE PHD 9650 ROCKVILLE PIKE NO 3411 BETHESDA MD 20814 101898167 0 X HTTP://WWW.FNIH.ORG X 2001 MD THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH. 27 26 52 0 0 0 73905546 33961606 197177 194500 148518 385451 199253 24552 74450494 34566109 57340984 43310618 0 0 5868172 6530244 0 0 184983 10868336 9228745 74077492 59069607 373002 -24503498 99015541 74645303 7446160 8169755 91569381 66475548 X SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH. 0 0 53079319 42319869 194500 SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPSPROGRAM ONE - RESEARCH PARTNERSHIPS - SINCE ITS ESTABLISHMENT NEARLY TWO DECADES AGO, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) HAS BECOME A LEADER IN FORGING POWERFUL PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BIOMEDICAL SCIENCE. WITH THE CAREFUL CRAFTING AND EXECUTION OF CUTTING-EDGE INITIATIVES, THE FNIH HELPS THE NATIONAL INSTITUTES OF HEALTH (NIH) TURN DISCOVERY INTO IMPROVED HEALTH. HIGHLIGHTS FROM FNIH'S 2015 PROGRAMMATIC PORTFOLIO ARE REFERENCED BELOW.FINDING BETTER MARKERS OF OSTEOARTHRITIS ONSET AND PROGRESSION OSTEOARTHRITIS DEVELOPS OVER TIME AS A JOINT'S "CUSHION" OF CARTILAGE BREAKS DOWN AND BONE ENDS RUB TOGETHER, CAUSING PAIN AND LOSS OF FUNCTION. KNEE OSTEOARTHRITIS (OA) IS THE LEADING CAUSE OF DISABILITY IN OLDER ADULTS AND AFFECTS ABOUT 250 MILLION PEOPLE WORLDWIDE. RIGHT NOW, OA IS DIAGNOSED ONLY AFTER PEOPLE HAVE DISCOMFORT, AND THE STANDARD TOOL IS AN X-RAY SHOWING JOINT SPACE NARROWING. BUT THE DISEASE PROCESS BEGINS LONG BEFORE SYMPTOMS APPEAR; IDENTIFYING THOSE AT RISK AND INTERVENING EARLIER COULD HELP AVOID COSTLY JOINT REPLACEMENTS. EARLIER DIAGNOSIS MAY SOON BE POSSIBLE THANKS TO THE OSTEOARTHRITIS BIOMARKERS PROJECT, A $3.4 MILLION STUDY LED BY THE FNIH BIOMARKERS CONSORTIUM IN PARTNERSHIP WITH THE NATIONAL INSTITUTE OF MUSCULOSKELETAL AND SKIN DISEASES, THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), UNIVERSITIES AND PHARMACEUTICAL COMPANIES TO IDENTIFY BIOMARKERS (BIOLOGICAL MARKERS) OF KNEE OA ONSET AND PROGRESSION. USING DATA FROM 5,000 HIGH-RISK PATIENTS GATHERED THROUGH THE NATIONAL INSTITUTES OF HEALTH OSTEOARTHRITIS INITIATIVE, ANOTHER PUBLIC-PRIVATE PARTNERSHIP THAT CREATED AN OPEN-ACCESS REPOSITORY OF MEDICAL IMAGES AND BLOOD AND URINE SAMPLES, THE FNIH-LED TEAM HAS NARROWED THOUSANDS OF POTENTIAL BIOMARKERS DOWN TO A SUBSET THAT CORRELATES WITH KNEE OA PROGRESSION. THESE INCLUDE BONE AND CARTILAGE CHANGES VISIBLE ON MRI AND PROTEINS DETECTABLE IN BLOOD AND URINE. THE BIOMARKERS CAN PAVE THE WAY TOWARD IDENTIFYING PEOPLE AT RISK AND DEVELOPING TREATMENTS THAT TARGET THE DISEASE PROCESS.IDENTIFYING NEW TARGETS TO DRIVE DRUG DEVELOPMENT LAUNCHED IN 2014, THE ACCELERATING MEDICINES PARTNERSHIP (AMP) IS A FIVE-YEAR, $230 MILLION EFFORT JOINING THE RESOURCES OF THE FNIH, THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE FDA WITH THOSE OF SEVERAL NONPROFIT ORGANIZATIONS AND BIOPHARMACEUTICAL COMPANIES TO DEVISE A MORE PRECISE APPROACH TO EARLY-STAGE DRUG DEVELOPMENT. THESE ORGANIZATIONS ARE SHARING EXPERTISE AND DATA TO IDENTIFY THE BIOLOGICAL PATHWAYS UNDERLYING FOUR DEVASTATING DISEASES-TYPE 2 DIABETES (T2D), RHEUMATOID ARTHRITIS/SYSTEMIC LUPUS ERYTHMATOSUS (RA/SLE) AND ALZHEIMER'S DISEASE (AD)-AND THEN VALIDATE THE BEST CANDIDATES FOR TARGETING NEW MEDICINES. AMP'S VISION IS TO EMPOWER RESEARCHERS TO PURSUE NEW TREATMENTS WITH BETTER ODDS OF MOVING THROUGH THE CLINICAL TRIALS PIPELINE SUCCESSFULLY. CURRENT THERAPIES FOR THESE CONDITIONS CANNOT REVERSE THE DISEASE PROCESS NOR STOP ITS PROGRESSION. IN 2015, THE AMP-T2D PROJECT PUBLICLY LAUNCHED A KNOWLEDGE PORTAL THAT HAS AMASSED LARGE AMOUNTS OF GENETIC AND CLINICAL DATA FROM AN ARRAY OF STUDIES ON PEOPLE WITH TYPE 2 DIABETES. THE PORTAL'S DATA COVER A WIDE VARIETY OF ETHNICITIES, INCLUDING AFRICAN-AMERICAN, EAST ASIAN, SOUTH ASIAN, EUROPEAN AND HISPANIC, AS WELL AS DIABETES-RELATED CARDIOVASCULAR AND KIDNEY COMPLICATIONS. RESEARCHERS WILL BE ABLE TO SEARCH AND ANALYZE THE DATA TO IDENTIFY GENETIC VARIANTS ASSOCIATED WITH INCREASED RISK FOR, OR PROTECTION AGAINST, THE DEVELOPMENT OF DIABETES AND ITS COMPLICATIONS. IN TURN, THESE CAN BECOME POTENTIAL TARGETS FOR NEW TREATMENTS. THE AMP-RA/SLE PROJECT HAS DEVELOPED NEW METHODS FOR ACQUIRING AND PROCESSING TISSUE FROM THE KIDNEYS AND SYNOVIAL MEMBRANES (LININGS OF JOINTS) AND TRAINED RESEARCHERS TO USE THESE METHODS, MAKING MULTI-SITE CLINICAL STUDIES POSSIBLE. THIS TISSUE, ALONG WITH BLOOD AND URINE SAMPLES, IS BEING UTILIZED TO GENERATE A NEW PUBLIC DATA REPOSITORY TO BE LAUNCHED IN 2016. FOR THE FIRST TIME, PARTNER ORGANIZATIONS WILL BE ABLE TO COLLABORATE ON GENOME-WIDE ANALYSIS OF THESE SAMPLES TO BETTER UNDERSTAND THE MECHANISMS BEHIND THE DESTRUCTION CAUSED BY RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHMATOSUS, BOTH DISEASES IN WHICH THE BODY'S IMMUNE SYSTEM DESTROYS HEALTHY TISSUE. AMP-AD INCLUDES TWO DIFFERENT PROJECTS. PROJECT A SEEKS TO VALIDATE EXISTING BIOMARKERS AS POSSIBLE INDICATORS OF RESPONSE TO TREATMENT IN PEOPLE WITH ALZHEIMER'S DISEASE. JUST ONE EXAMPLE IS PET IMAGING OF TAU PROTEINS IN THE BRAIN, WHICH HAS BEEN ADDED TO TWO MAJOR NIH-FUNDED PHASE II/III DRUG TRIALS. PROJECT B IS WORKING TO ACCELERATE THE DISCOVERY OF NEW THERAPEUTIC TARGETS, MOVING BEYOND THE TRADITIONAL FOCUS ON THE BUILDUP OF PROTEINS SUCH AS AMYLOID AND TAU IN BRAIN TISSUE. RESEARCHERS BUILD A DEEPER UNDERSTANDING OF THE NETWORKS IN WHICH THESE NOVEL TARGETS OPERATE AND VALIDATE THEM IN DIFFERENT MODELS. THE PROJECT INTEGRATES ANALYSIS OF LARGE-SCALE MOLECULAR DATA FROM MORE THAN 2,000 HUMAN BRAINS AT ALL STAGES OF THE DISEASE WITH NETWORK MODELING APPROACHES AND EXPERIMENTAL VALIDATION. THIS PROJECT HAS CREATED A KNOWLEDGE PORTAL THAT ENABLES RAPID, BROAD SHARING OF DATA AND ANALYTICAL TOOLS, AND PERIODICALLY RELEASES PUBLIC WAVES OF LARGE-SCALE MOLECULAR DATA FROM HUMAN BRAIN SAMPLES. THE ULTIMATE GOAL IS TO SHORTEN THE TIME BETWEEN DISCOVERY OF POTENTIAL DRUG TARGETS TO DEVELOPMENT OF NEW DRUGS FOR ALZHEIMER'S TREATMENT AND PREVENTION.IDENTIFYING BIOMARKERS IN CHILDREN TO HELP ADVANCE AUTISM RESEARCH AN AVERAGE OF ONE IN EVERY 68 EIGHT-YEAR-OLD CHILDREN IN THE UNITED STATES IS DIAGNOSED WITH AUTISM SPECTRUM DISORDER (ASD), TYPICALLY BASED ON BEHAVIORAL OBSERVATIONS BY PARENTS AND CAREGIVERS-BUT THESE BEHAVIORS CAN RANGE WIDELY. DEVELOPING EFFECTIVE INTERVENTIONS AND TREATMENTS THROUGH CLINICAL TRIALS DEPENDS ON DEVELOPING MORE SENSITIVE AND OBJECTIVE STANDARDS FOR DIAGNOSING ASD IN CHILDREN AND EVALUATING CHANGE OVER TIME. IN 2015, THE FNIH PARTNERED WITH THE NATIONAL INSTITUTE OF MENTAL HEALTH, SIMONS FOUNDATION AUTISM RESEARCH INITIATIVE (SFARI), FDA, JANSSEN RESEARCH & DEVELOPMENT, LLC AND EUROPEAN AUTISM INTERVENTIONS - A MULTICENTRE STUDY FOR DEVELOPING NEW MEDICATIONS (EU-AIMS) TO SUPPORT A STUDY OF PRESCHOOL AND SCHOOL-AGED CHILDREN WITH ASD TO VALIDATE BIOMARKERS THAT COULD HELP ASSESS SOCIAL FUNCTION, TRACK CHANGES IN BEHAVIOR AND NEUROLOGIC FUNCTION, AND POTENTIALLY EVALUATE THE EFFECTIVENESS OF PHARMACOLOGIC TREATMENTS. THE FNIH IS MANAGING A $2 MILLION CONTRIBUTION FROM SFARI TO FUND THE YALE UNIVERSITY STUDY LED BY JAMES MCPARTLAND, PH.D., PRINCIPAL INVESTIGATOR, WHICH IS COLLECTING DATA FROM CHILDREN AT FIVE SITES NATIONWIDE USING ASSESSMENTS OF SOCIAL IMPAIRMENT, SUCH AS CLINICIAN, CAREGIVER AND LAB-BASED TOOLS; NEUROPHYSIOLOGICAL MEASURES, SUCH AS EYE TRACKING AND STUDIES OF BRAIN ACTIVITY (EEG, OR ELECTROENCEPHALOGRAM); AND BLOOD SAMPLES FROM PARTICIPANTS AND THEIR PARENTS FOR GENETIC ANALYSIS. THIS $28 MILLION LARGE-SCALE U.S. PARTNERSHIP TO IDENTIFY BIOMARKERS ASSOCIATED WITH ASD IS PART OF THE FNIH BIOMARKERS CONSORTIUM.BUILDING RESEARCH INFRASTRUCTURE IN AFRICATO DEVELOP THE NEW VACCINES AND TREATMENTS THAT IMPROVE PUBLIC HEALTH, RESEARCHERS REQUIRE ACCESS TO HIGH-PERFORMANCE COMPUTING RESOURCES FOR COLLECTING AND ANALYZING COMPLEX BIOLOGICAL DATA. MANY LOW-INCOME COUNTRIES LACK THE INFRASTRUCTURE NEEDED FOR BIOINFORMATICS RESEARCH, EVEN AS THEY FACE SOME OF THE WORLD'S MOST CHALLENGING AND OFTEN-NEGLECTED DISEASES. LAST YEAR, THE FNIH PLAYED A PIVOTAL ROLE IN HELPING THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) LAUNCH THE FIRST AFRICAN CENTER OF EXCELLENCE IN BIOINFORMATICS (ACE) IN MALI, WEST AFRICA. BUILDING ON NIAID'S ONGOING SUPPORT FOR RESEARCHERS IN MALI, THE FNIH INVITED CORPORATE PARTNERS SUCH AS THE BIOTEAM INC., INTEL CORPORATION HEALTH AND LIFE SCIENCES GROUP, THE EMC CORPORATION AND HEWLETT PACKARD ENTERPRISE TO DONATE EQUIPMENT FOR COMPUTING AND DATA ANALYSIS, HIGH-SPEED CONNECTIVITY, AND RESEARCH AND CLASSROOM SPACES. MALI ACE OPENED IN APRIL 2015 AT THE UNIVERSITY OF SCIENCES, TECHNIQUES AND TECHNOLOGY OF BAMAKO (USTTB). LOCAL RESEARCHERS ARE NOW ABLE TO CONDUCT ADVANCED BIOINFORMATICS RESEARCH WHILE RECEIVING LONG-DISTANCE TRAINING AND MENTORSHIP BY NIAID RESEARCHERS. MALI ACE WILL SERVE AS A MODEL FOR FUTURE BIOINFORMATICS RESEARCH CENTERS IN OTHER REGIONS OF AFRICA.CONTINUING IN THE SEARCH FOR AN HIV VACCINE SINCE THE MID-1990S, THE SUCCESSFUL DEVELOPMENT OF MEDICATIONS FOR PEOPLE WITH HUMAN IMMUNODEFICIENCY VIRUS, OR HIV, HAS DEFLECTED SOME ATTENTION FROM THE SEARCH FOR A PREVENTIVE VACCINE. BUT NO MEDICINE HAS CURED HIV, AND ONLY ABOUT HALF OF THE MORE THAN 33 MILLION HIV-POSITIVE PEOPLE WORLDWIDE CAN ACCESS TREATMENT. A SUCCESSFUL VACCINE IS STILL CONSIDERED FUNDAMENTAL FOR CONQUERING HIV/AIDS. FOR NEARLY 10 YEARS, THE FNIH HAS SERVED AS COORDINATOR FOR THE COMPREHENSIVE T CEL 1210274 891762 SEE SCHEDULE O, PROGRAM TWO, FELLOWSHIPS AND TRAINING PROGRAMSPROGRAM TWO - FELLOWSHIPS AND TRAINING PROGRAMS - RECOGNIZING GROUNDBREAKING WORK BY EARLY-CAREER SCIENTISTS DUE TO STEADY DECLINES IN FINANCIAL SUPPORT FOR BASIC SCIENCE RESEARCH, TODAY'S YOUNG SCIENTISTS FACE A CHALLENGING ENVIRONMENT IN WHICH TENURE-TRACK UNIVERSITY POSITIONS ARE SCARCE AND ABOUT 85 PERCENT OF RESEARCH GRANT PROPOSALS ARE UNFUNDED. IT IS NOT UNUSUAL FOR BIOMEDICAL RESEARCHERS TO REACH THEIR LATE 30S OR 40S BEFORE RECEIVING A MAJOR RESEARCH GRANT-AND THIS AFFECTS THEIR ABILITY TO MAKE SIGNIFICANT, CAREER-CHANGING DISCOVERIES. THREE YEARS AGO, THE FNIH ESTABLISHED THE LURIE PRIZE IN BIOMEDICAL SCIENCES, NAMED FOR PHILANTHROPIST AND BOARD MEMBER ANN LURIE, TO HELP PROPEL THE WORK OF ONE TRULY STELLAR, EARLY-CAREER RESEARCHER EACH YEAR. THE PRESTIGIOUS PRIZE, WHICH INCLUDES A MEDAL AND SIGNIFICANT RESEARCH HONORARIUM, IS AWARDED AT A WASHINGTON, DC CEREMONY EVERY SPRING. THE 2015 LURIE PRIZE WINNER WAS HOWARD HUGHES MEDICAL INSTITUTE INVESTIGATOR AND STANFORD UNIVERSITY NEUROSCIENTIST AND PSYCHIATRIST KARL DEISSEROTH, M.D., PH.D., WHO ALONG WITH HIS TEAM HAS PIONEERED TWO GAME-CHANGING TECHNIQUES: OPTOGENETICS, WHICH USES LIGHT TO MAP THE NEURAL CIRCUITS IN OUR BRAINS, AND A TECHNOLOGY CALLED CLARITY THAT ALLOWS SCIENTISTS TO MAKE ORGANS TRANSPARENT AND THEREFORE EASIER TO STUDY UNDER A MICROSCOPE. IN HIS HANDS, BOTH PROMISE TO REVOLUTIONIZE OUR APPROACH TO NEUROLOGICAL DISEASES SUCH AS MAJOR DEPRESSION, ALZHEIMER'S AND PARKINSON'S.PREVENTING COGNITIVE DECLINE AGE-RELATED DECLINE IN COGNITIVE FUNCTION IS REAL AND VARIES WIDELY AMONG INDIVIDUALS, INFLUENCING QUALITY OF LIFE, CHARACTER OF PERSONAL RELATIONSHIPS AND CAPACITY FOR MAKING INFORMED DECISIONS ABOUT HEALTH CARE, RETIREMENT AND OTHER ISSUES FACED DAILY BY MILLIONS OF OLDER ADULTS. IN 2007, THE MCKNIGHT BRAIN RESEARCH FOUNDATION (MBRF) PARTNERED WITH THE FNIH AND THE NATIONAL INSTITUTE ON AGING (NIA) TO FUND THE FIRST COGNITIVE AGING SUMMIT, WHERE DOZENS OF RESEARCHERS SHARED IDEAS ABOUT HOW BEST TO UNDERSTAND AND REMEDIATE AGE-RELATED COGNITIVE DECLINE. THE SUMMIT LED TO THE RESEARCH PARTNERSHIP IN COGNITIVE AGING IN 2008, A PUBLIC-PRIVATE EFFORT BETWEEN THE NIA AND THE MBRF. BEGINNING IN 2009, THE PARTNERSHIP FUNDED TWO RESEARCH INITIATIVES, 17 GRANTS TOTALING $28 MILLION OVER FIVE YEARS. THE PARTNERSHIP SUPPORTED A SECOND SUMMIT IN 2010, WITH RECOMMENDATIONS LEADING TO A THIRD JOINT INITIATIVE FOCUSED ON INTERVENTIONS. IN 2014, THE PARTNERSHIP, ALONG WITH THE NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH AND THE NIH OFFICE OF BEHAVIORAL AND SOCIAL SCIENCES RESEARCH, FUNDED THE $15 MILLION MEDEX (MINDFULNESS, HEALTH EDUCATION, & EXERCISE) TRIAL. NOW UNDERWAY, THE TRIAL IS COMPARING THE EFFECTIVENESS OF MINDFULNESS-BASED STRESS REDUCTION, BRAIN HEALTH EDUCATION AND AEROBIC EXERCISE AS STRATEGIES FOR IMPROVING COGNITIVE FUNCTION.EDMOND J. SAFRA FAMILY LODGE: 10 YEARS OF CARING ON NOVEMBER 5, 2015, THE FNIH WELCOMED BOARD MEMBER AND GUEST OF HONOR MRS. LILY SAFRA TO CELEBRATE THE 10TH ANNIVERSARY OF THE EDMOND J. SAFRA FAMILY LODGE, WHICH SINCE 2005 HAS HOSTED MORE THAN 100,000 ROOM NIGHTS FOR PATIENTS OF THE NIH CLINICAL CENTER AND THEIR FAMILIES. THE FAMILY LODGE PROVIDES A HOME-LIKE SETTING FREE OF CHARGE FOR GUESTS FROM ACROSS THE NATION AND AROUND THE WORLD. THIS SERVICE EXISTS THANKS TO THE GENEROSITY OF THE EDMOND J. SAFRA PHILANTHROPIC FOUNDATION AND MANY OTHER INDIVIDUAL DONORS, CORPORATIONS AND FOUNDATIONS. MRS. LILY SAFRA DONATED PROCEEDS FROM HER JEWELS FOR HOPE AUCTION TO SUPPORT THE PRESERVATION OF THE FAMILY LODGE ACCORDING TO HER VISION.MEDICATION DONATIONS HELP REDIRECT FUNDS TO RESEARCH SINCE 2009, SANOFI FOUNDATION FOR NORTH AMERICA AND NOVARTIS PHARMACEUTICALS CORPORATION HAVE DONATED MORE THAN $6.4 MILLION IN MEDICATIONS TO THE NIH CLINICAL CENTER THROUGH THE FNIH'S IN-KIND DRUG DONATION PROGRAM, FREEING UP CRITICAL DOLLARS FOR RESEARCH. THE CENTER IS THE NATION'S LARGEST HOSPITAL ENTIRELY DEVOTED TO CLINICAL RESEARCH, AND PATIENTS RECEIVE ALL CARE FREE OF CHARGE.MORE FELLOWSHIPS FOR KIDNEY CANCER RESEARCH OCTOBER 4, 2015, MARKED THE 10TH ANNIVERSARY OF THE BOO! RUN FOR LIFE EVENT IN WASHINGTON, DC TO BENEFIT THE DEAN R. O'NEILL RENAL CELL CANCER FUND. THIS FUND, TOGETHER WITH THE DR. EDWARD T. RANCIC MEMORIAL CANCER RESEARCH FUND, SUPPORTS A ROTATION OF FULL-TIME FELLOWS IN THE LABORATORY OF DR. RICHARD CHILDS OF THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE, WHERE THEY FOCUS ON DEVELOPING NOVEL THERAPIES FOR ADVANCED KIDNEY CANCER. SUPPORT FOR A NEW GENERATION OF RESEARCH SCIENTISTS IN FALL 2015, TWO YOUNG SCHOLARS AT THE NIH WERE AWARDED FULL FUNDING FOR THEIR FIRST YEAR OF EDUCATION AND TRAINING, THANKS TO A GENEROUS GIFT TO THE FNIH BY THE JAYNE KOSKINAS TED GIOVANIS (JKTG) FOUNDATION FOR HEALTH AND POLICY. JOSE DELGADO-JIMENEZ RECEIVED AN NIH POSTBACCALAUREATE INTRAMURAL RESEARCH TRAINING AWARD/CANCER RESEARCH TRAINING AWARD (POSTBAC IRTA/CRTA), WHICH OFFERS RECENT COLLEGE GRADUATES WHO PLAN TO APPLY TO GRADUATE OR HEALTH PROFESSIONAL SCHOOL THE OPPORTUNITY TO SPEND ONE OR TWO YEARS PERFORMING FULL-TIME RESEARCH AT THE NIH. JOSE HAS A SPECIAL INTEREST IN NANOTECHNOLOGY AND CANCER THERAPEUTICS. THE JKTG FOUNDATION GIFT ALSO SUPPORTED A SCHOLARSHIP TO NIH'S GRADUATE PARTNERSHIP PROGRAM (GPP), WHICH BRINGS PH.D. STUDENTS TO THE NIH INTRAMURAL RESEARCH PROGRAM FOR DISSERTATION RESEARCH. AWARDEE RYAN PHILLIPS' RESEARCH INTERESTS INCLUDE MATHEMATICAL/ MOLECULAR MODELING AND BRAIN CIRCUITRY. BOTH STUDENTS ARE WORKING SIDE-BY-SIDE WITH SOME OF THE LEADING SCIENTISTS IN THE WORLD AND EXPERIENCING THE COLLABORATIVE, INTERDISCIPLINARY RESEARCH ENVIRONMENT THAT NIH HAS TO OFFER.NEW FUNDING, NEW CAREER PATHWAYSTWO MAJOR GRANTS THROUGH THE FNIH ARE HELPING THE NIH CREATE NEW CAREER-BUILDING OPPORTUNITIES FOR ASPIRING RESEARCHERS. THANKS TO AN $850,000 GRANT FROM THE AMGEN FOUNDATION, THE NIH IS NOW ONE OF A SELECT GROUP OF HIGHER LEARNING INSTITUTIONS TAKING PART IN THE AMGEN SCHOLARS PROGRAM, WHICH PROVIDES HUNDREDS OF SUMMER RESEARCH OPPORTUNITIES TO UNDERGRADUATE STUDENTS. A $200,000 GIFT FROM THE CONGRESS OF NEUROLOGICAL SURGEONS (CNS) HAS CREATED THE NINDS/CNS GETCH SCHOLAR AWARD IN COLLABORATION WITH THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS). THIS COMPETITIVE AWARD WILL PROVIDE TWO YEARS OF FUNDING TO HELP AN EARLY-CAREER NEUROSURGEON LAUNCH A CLINICAL AND RESEARCH CAREERLAUNCHING WOMEN INTO RESEARCH CAREERS IN 2015, THE SALLIE ROSEN KAPLAN POSTDOCTORAL FELLOWSHIP FOR WOMEN SCIENTISTS IN CANCER RESEARCH (SRK) PROGRAM WELCOMED 10 OUTSTANDING POST-DOCTORAL NATIONAL CANCER INSTITUTE RESEARCHERS-ALL FEMALE AND SOME FROM UNDERREPRESENTED MINORITY GROUPS-TO PARTICIPATE IN LEADERSHIP WORKSHOPS AND SEMINARS, RECEIVE MENTORING AND COACHING AND DEVELOP A PEER NETWORK. THE PROGRAM IS DESIGNED TO HELP WITH THEIR TRANSITION TO INDEPENDENT RESEARCH CAREERS.HUMAN GENOME EXHIBIT ON TOUR THREE MILLION SMITHSONIAN VISITORS TOURED GENOME: UNLOCKING LIFE'S CODE FROM JUNE 2013 TO AUGUST 2014 AT THE NATIONAL MUSEUM OF NATURAL HISTORY, AN EXHIBITION MADE POSSIBLE THROUGH FUNDS RAISED, IN PART, BY THE FNIH. THE RESULT OF A COLLABORATION BETWEEN THE MUSEUM AND THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE, GENOME SHOWCASED THE COMPLEXITY AND POWER OF THE HUMAN GENOME USING 3-D MODELS, INTERACTIVE DISPLAYS, CUSTOM ANIMATIONS AND REAL-LIFE STORIES. THE EXHIBIT IS NOW ON A FIVE-YEAR TOUR TO MUSEUMS AND SCIENCE CENTERS ACROSS NORTH AMERICA.- 2015 HOST CITIES: PORTLAND, SAINT LOUIS, SAN DIEGO AND SAN JOSE - 2016 HOST CITIES: MILWAUKEE (JAN. 23-APRIL 25), SALT LAKE CITY (MAY 21-SEPT. 5) AND WICHITA (SEPT. 30 - JAN. 1, 2017) 734853 88504 SEE SCHEDULE O, PROGRAM THREE, MEMORIALS, AWARDS AND EVENTSPROGRAM THREE - MEMORIALS, AWARDS AND EVENTS - COLLABORATION HAPPENS WHEN PEOPLE CONNECT. THAT IS WHY MANAGING AND ORGANIZING MEETINGS AND EVENTS IS FUNDAMENTAL TO THE WORK OF THE FNIH. FROM LECTURES AND WORKSHOPS TO COLLABORATIVE SUMMITS, TELECONFERENCES AND MEDIA OPPORTUNITIES, THE FNIH FACILITATED MORE THAN 50 EVENTS IN 2015 - SPANNING THE GLOBE AND DOZENS OF FIELDS OF RESEARCH. 313270 10484 PROGRAM FOUR - CAPITAL PROJECTS - THE FOUNDATION'S CAPITAL PROJECTS ENHANCE THE RESEARCH ENVIRONMENT AT NIH, SUPPORTING AND PROMOTING THE IMPORTANT DISCOVERIES THAT RESULT FROM NIH'S LEADING-EDGE WORK. THE EDMOND J. SAFRA FAMILY LODGE, FOR EXAMPLE, OPENED IN 2005 TO SERVE AS A COMFORTABLE HOME-AWAY-FROM-HOME FOR FAMILIES THAT COME TO NIH'S CAMPUS IN BETHESDA, MARYLAND TO ACCOMPANY PATIENTS WHO ARE PARTICIPATING IN CLINICAL TRIALS OR RECEIVING TREATMENT AT NIH'S CLINICAL CENTER. SO FAR, THE LODGE HAS HOSTED MORE THAN 40,000 FAMILY MEMBERS AND CAREGIVERS OF ADULT PATIENTS FROM ALL OVER THE WORLD. 313270 10484 55337716 1 1 0 0 0 1 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 28 0 1 52 1 0 0 0 0 0 0 0 0 0 0 X 27 26 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD VA NY AL AK AR CA CO CT FL GA HI IL KS KY ME MA MI MS MN NH NJ NM NC ND OH OK OR PA RI SC TN UT WA WV WI X X JULIE TUNE 3014025311 9650 ROCKVILLE PIKE BETHESDA MD 20814 DR CHARLES A SANDERS CHAIRMAN 1.50 X X 0 0 0 STEVEN C MAYER TREASURER 2.00 X X 0 0 0 THE HON JOHN EDWARD PORTER VICE-CHAIRMAN FOR POLICY 1.00 X X 0 0 0 MRS WILLIAM MCCORMICK BLAIR JR SECRETARY 1.00 X X 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 40.00 X X 385293 0 26500 DR SOLOMON H SNYDER VICE-CHAIRMAN FOR SCIENCE 0.50 X X 0 0 0 DR PAUL M MONTRONE BOARD MEMBER 1.00 X 0 0 0 DAME JILLIAN SACKLER BOARD MEMBER 0.50 X 0 0 0 LILY SAFRA BOARD MEMBER 0.50 X 0 0 0 DR ELLEN V SIGAL BOARD MEMBER 0.50 X 0 0 0 DR STEVEN M PAUL BOARD MEMBER 0.50 X 0 0 0 MRS WILLIAM BUFFY N CAFRITZ BOARD MEMBER 0.50 X 0 0 0 DR SAMUEL O THIER BOARD MEMBER 0.50 X 0 0 0 DR MARTIN J MURPHY JR BOARD MEMBER 0.50 X 0 0 0 DR KATHY BLOOMGARDEN BOARD MEMBER 0.50 X 0 0 0 DR JOSEPH M FECZKO BOARD MEMBER 0.50 X 0 0 0 ANN LURIE BOARD MEMBER 0.50 X 0 0 0 DR FREDA C LEWIS-HALL BOARD MEMBER 0.50 X 0 0 0 ANNE WOJCICKI BOARD MEMBER 0.50 X 0 0 0 NINA K SOLARZ BOARD MEMBER 0.50 X 0 0 0 JAMES H DONOVAN BOARD MEMBER 0.50 X 0 0 0 DR PAUL L HERRLING BOARD MEMBER 0.50 X 0 0 0 DR RONALD L KRALL BOARD MEMBER 0.50 X 0 0 0 DR EDISON T LIU BOARD MEMBER 0.50 X 0 0 0 DR JUDY LANSING KOVLER BOARD MEMBER 0.50 X 0 0 0 JOEL S MARCUS BOARD MEMBER 0.50 X 0 0 0 RUSSELL W STEENBERG BOARD MEMBER 0.50 X 0 0 0 STEPHANIE JAMES DIRECTOR OF SCIENCE & DIRECTOR, GCGH 40.00 X 296788 0 26500 DAVID WHOLLEY DIRECTOR OF RESEARCH PARTNERSHIPS 40.00 X 298288 0 38333 ANN ASHBY DEPUTY EXECUTIVE DIRECTOR 40.00 X 154960 0 23424 ANDREA BARUCHIN SENIOR ADVISOR TO THE PRESIDENT 40.00 X 173670 0 21937 JULIE TUNE CHIEF FINANCIAL OFFICER 40.00 X 197756 0 31609 JULIA WOLF-RODDA DIRECTOR OF DEVELOPMENT 40.00 X 196429 0 31476 MICHAEL GOTTLIEB ASSOCIATE DIRECTOR OF SCIENCE 40.00 X 241098 0 24110 KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 40.00 X 160218 0 27855 STEVE HOFFMANN SCIENTIFIC PROGRAM MANAGER 40.00 X 146862 0 26519 MELISSA CATHER DIRECTOR OF ADVANCEMENT 40.00 X 143480 0 14348 ROSA CANET AVILES SCIENTIFIC PROGRAM MANAGER 40.00 X 141265 0 25960 2536107 0 318571 21 0 1 0 BUSINESS TALENT GROUP 406 BLACKWELL STREET SUITE 240A DURHAM NC 27701 CONSULTING 808539 ICON EARLY PHASE SERVICES LLC PO BOX 28939 NEW YORK NY 10087 CLINICAL TRIAL 513095 CCS ASSOCIATES INC PO BOX 9125 MCLEAN VA 22102 CONSULTING 350345 THE UNIVERSITY OF TEXASMD ANDERSON PO BOX 4390 HOUSTON TX 77210 CLINICAL TRIAL 328872 MCKINSEY & COMPANY INC PO BOX 7247-7255 PHILADELPHIA PA 19170 SERVICES TO CONDUCT STUDY 300000 22 39000 1000000 32922606 677982 33961606 ADMINISTRATIVE FEES 561000 194500 194500 194500 367897 367897 67156014 67138460 17554 17554 17554 218150 39000 193598 24552 24552 34566109 194500 0 410003 29562490 29562490 10550 10550 13737578 13737578 1897600 742067 1129340 26193 3290679 2175259 1016337 99083 360718 196197 148885 15636 630127 386685 233318 10124 351120 171898 179222 175183 170954 4229 55585 55585 73418 19733 53685 14756 14756 32578 21475 10676 427 165537 76845 75310 13382 519802 247876 271926 1434971 1361729 71596 1646 21850 21850 193885 145139 48746 PROGRAM CONTRACTS 3940944 3940944 CONSULTANTS 2226968 2069695 157273 PRINTING AND PHOTOCOPYI 251809 238461 2473 10875 HONORARIA 160900 160900 -39441 -113515 66457 7617 59069607 55337716 3546908 184983 20242543 21131272 19827866 10084867 65998 84024 680486 630146 54336 50340 58789274 43250167 35524 44633 99015541 74645303 1338401 1460257 4605461 5975257 1338837 577271 163461 156970 7446160 8169755 X 11758572 11662389 76594675 51608294 3216134 3204865 91569381 66475548 99015541 74645303 -24503498 -590335 0 X X 0 1 X 1 0 X 59765254 58869026 59135001 73905546 33961607 285636434 59765254 58869026 59135001 73905546 33961607 285636434 152448314 133188120 134140 140900 213728 214303 367897 1070968 286707402 2635799 0.46450 0.48930 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2 1525 5600 4134027 1 1 0 1 X 9616660 10356 -100829 24616 9501571 3381374 6271975 11641 48330 9616660 3491739 14559 -83704 41220 3381374 3498900 15153 25879 48193 3491739 3558830 3214 -91 63053 3498900 0.65000 0.34000 0.01000 0 0 680486 630146 50340 50340 CHARITABLE GIFT ANNUITY 156970 156970 X 34505611 -590335 336239 -254096 34759707 -193598 -193598 34566109 59599444 336239 193598 529837 59069607 0 59069607 PART IV, LINE 2B: AS OF 12/31/2015, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC HELD $577,271 IN AGENCY FUNDS FOR FUTURE DISTRIBUTIONS TO THE NATIONAL INSTITUTES OF HEALTH (NIH). THESE FUNDS ARE DESIGNATED BY THE FUNDER(S) FOR SPECIFIC PROJECTS AT THE NIH, AND WILL BE DISBURSED AS NEEDED. PART V, LINE 4: THE FOUNDATION'S ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSES. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS. PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2015 AND 2014. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE -193,598. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE 193,598. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 3876242 EUROPE 0 0 GRANTMAKING 9072296 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 199799 SOUTH ASIA 0 0 GRANTMAKING 589241 0 0 0 0 0 0 13737578 0 13737578 SOUTH ASIA MALNUTRITION & ENTERIC DISEASES NETWORK 313097 WIRE TRANSFER SOUTH ASIA MALNUTRITION & ENTERIC DISEASES NETWORK 276144 WIRE TRANSFER EUROPE DEVELOP A GENETIC STRATEGY TO DEPLETE OR INCAPACITATE INSECTS/VIMC2 7892944 WIRE TRANSFER EAST ASIA AND THE PACIFIC MODIFYING MOSQUITO POPULATION AGE STRUCTURE TO ELIMINATE DENGUE TRANSMISSION-ELIMINATE DENGUE 3866242 WIRE TRANSFER EUROPE IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 489924 WIRE TRANSFER EAST ASIA AND THE PACIFIC BIOMARKERS OSTEOARTHRITIS 10000 WIRE TRANSFER SUB-SAHARAN AFRICA IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 199799 WIRE TRANSFER EUROPE AMP-T2 DIABETES 104365 WIRE TRANSFER EUROPE IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 585063 WIRE TRANSFER 9 0 0 0 0 0 0 PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. 2015 FNIH AWARD CEREMONY 247150 39000 208150 30249 155576 2016 FNIH AWARD CEREMONY 10000 10000 7773 257150 39000 218150 30249 163349 193598 24552 1 BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 221973 NON HUMAN PRIMATE NEW ASSAY BRIGHAM AND WOMEN'S HOSPITAL 1620 TREMONT STREET 3RD FLOOR RM BC 3002 BOSTON MA 02120 042312909 501(C)(3) 50836 EVALUATION OF THE EFFECTS OF FCRN MUTATIONS ON ANTIBODY HALF-LIFE.+ KIDNEY CASE WESTERN RESERVE UNIVERSITY NORD HALL SUITE 615 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(C)(3) 587000 CTVIMC2-MOLECULAR IMMUNE CORRELATES CORE DONALD DANFORTH PLANT SCIENCE CENTER 975 NORTH WARSON ROAD ST LOUIS MO 63132 311584621 501(C)(3) 166572 REGULATORY DEVELOPMENT FOR HEG-MODIFIED MOSQUITOES DUKE UNIVERSITY 2200 WEST MAIN STREET SUITE 820 ERWIN SQUARE PLAZA DURHAM NC 27705 560532129 501(C)(3) 635888 PROFICIENCY TESTING CENTRAL/CTVIMC2/BIOMARKERS-CECI FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 544993 CTVIMC2/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM FRIENDS OF CANCER RESEARCH 1800 M STREET NW SUITE 1050 SUTH WASHINGTON DC 20036 521983273 501(C)(3) 50000 LUNGCANCER PROTOCOL HENRY JACKSON FOUNDATION (USMHRP) 1401 ROCKVILLE PIKE SUITE 600 ROCKVILLE MD 20852 521317896 501(C)(3) 238614 PROFICIENCY TESTING/MAL-ED ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 99905 AMP-T2 DIABETES JOHNS HOPKINS UNIVERSITY 615 N WOLFE ST W1100 BALTIMORE MD 21205 150595110 501(C)(3) 500000 MAL-ED NIA INC OF GREATER RICHMOND 4247 CREIGHTON ROAD RICHMOND VA 23223 541736110 501(C)(3) 201000 HEART TRUTH-WOMEN TAKE CARE CHARGE NEW YORK BLOOD CENTER 310 EAST 67TH STREET NEW YORK NY 10065 131949477 501(C)(3) 68483 OVAF NIH- NINR 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 8081 RESEARCH NIH- CLINICAL CENTER 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 564762 RESEARCH NIHOD 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 199099 RESEARCH NIHFIC 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 794736 RESEARCH NIHNCI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858116 170(C)(1) GOVT 799544 RESEARCH NIHNHLBI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858117 170(C)(1) GOVT 1134327 RESEARCH NIHNIA 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 9024691 RESEARCH NIHNIAID 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 2723221 RESEARCH NIHNIAMS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 3000000 RESEARCH NIHNIMH 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 408553 RESEARCH NIHNIDDK 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 185854 RESEARCH NIHNINDS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 2820368 RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET 1040 WOLVERINE TOWER ANN ARBOR MI 48109 386006309 170(C)(1) GOVT 750852 AMP-T2 DIABETES. DEPOSIT OF METSIM AND FUSION DATA INTO KNOWLEDGE PORTAL THOMAS JEFFERSON UNIVERSITY 125 SOUTH 9TH ST 2ND FLOOR SHERIDAN BUILDING PHILADELPHIA PA 19107 231352651 501(C)(3) 195535 OVAF THE HOPE HEART INSTITUTE 1380 112TH AVENUE NORTHEAST SUITE 200 BELLEVUE WA 98004 911138000 501(C)(3) 152325 HEART TRUTH GRANT THE PENNYSLVANIA STATE UNIVERSITY 401 RIDER BLDG 227 W BEAVER AVE STATE COLLEGE PA 16801 246000376 170(C)(1) GOVT 247311 MAL-ED UNIVERSITY OF CALIFORNIA SAN FRANCISCO MISSION HALL 550 16TH STREET 2ND FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 249500 OSTEOARTHRITIS/BONE QUALITY THE UNIVERSITY OF CALIFORNIA (RIVERSIDE) 200 UNIVERSITY OFFICE BUILDING RIVERSIDE RIVERSIDE CA 925210217 956006142 170(C)(1) GOVT 200000 HEART TRUTH- NAVIGATING PACIFIC HEARTS UNIVERSITY OF SOUTHERN CALIFORNIA SOTO STREET BUILDING 2001 SOTO STREET LOS ANGELES CA 900899235 911642394 501(C)(3) 1150000 AMP-AD TAU PET IMAGING -ALZHEIMER'S THERAPEUTIC RESEARCH INSTITUTE (USC ATRI) A4 TRIAL UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 546001796 170(C)(1) GOVT 1395263 MAL-ED WEST VIRGINIA UNIVERSITY RESEARCH 886 CHESNUT RIDGE ROAD ROOM 202 MORGANTOWN WV 26506 550665758 501(C)(3) 193204 HEART TRUTH - LOVE YOUR HEART MOVEMENT 33 AWARDS 8 10550 FMV PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE. X X X 0 0 0 0 0 0 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 385293 0 0 0 0 0 26500 0 0 0 411793 0 0 0 STEPHANIE JAMES DIRECTOR OF SCIENCE & DIRECTOR, GCGH 296788 0 0 0 0 0 26500 0 0 0 323288 0 0 0 DAVID WHOLLEY DIRECTOR OF RESEARCH PARTNERSHIPS 290738 0 5000 0 2550 0 26500 0 11833 0 336621 0 0 0 ANN ASHBY DEPUTY EXECUTIVE DIRECTOR 154648 0 0 0 312 0 15496 0 7928 0 178384 0 0 0 ANDREA BARUCHIN SENIOR ADVISOR TO THE PRESIDENT 173670 0 0 0 0 0 17367 0 4570 0 195607 0 0 0 JULIE TUNE CHIEF FINANCIAL OFFICER 197256 0 0 0 500 0 19776 0 11833 0 229365 0 0 0 JULIA WOLF-RODDA DIRECTOR OF DEVELOPMENT 191429 0 3000 0 2000 0 19643 0 11833 0 227905 0 0 0 MICHAEL GOTTLIEB ASSOCIATE DIRECTOR OF SCIENCE 241098 0 0 0 0 0 24110 0 0 0 265208 0 0 0 KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 160218 0 0 0 0 0 16022 0 11833 0 188073 0 0 0 STEVE HOFFMANN SCIENTIFIC PROGRAM MANAGER 138862 0 8000 0 0 0 14686 0 11833 0 173381 0 0 0 MELISSA CATHER DIRECTOR OF ADVANCEMENT 143480 0 0 0 0 0 14348 0 0 0 157828 0 0 0 ROSA CANET AVILES SCIENTIFIC PROGRAM MANAGER 138973 0 0 0 2292 0 14127 0 11833 0 167225 0 0 0 X 3 28893 STOCK PRICE X 2 645974 MARKET PRICE X DONATED GOODS 1 3115 MARKET PRICE 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 DR. FREIRE, PRESIDENT OF THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC. (FNIH), IS A NON-EXECUTIVE MEMBER OF THE BOARD OF DIRECTORS OF ALEXANDRIA REAL ESTATE EQUITIES (ARE). MR. JOEL MARCUS, CEO AND CHAIRMAN OF ARE IS A NON-EXECUTIVE MEMBER OF THE FNIH BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11 PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE FINAL FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. BOARD DIRECTORS SHALL BE PROVIDED WITH AT LEAST TEN BUSINESS DAYS TO REVIEW THE FORM AND RAISE QUESTIONS, MAKE SUGGESTIONS, AND ADDRESS ANY POTENTIAL PROBLEMS OR CONCERNS WITH THE CHIEF FINANCIAL OFFICER. A SPECIAL MEETING OF THE GOVERNANCE COMMITTEE WILL BE CALLED TO REVIEW THE SUGGESTED CHANGES FROM THE BOARD OF DIRECTORS AND TO APPROVE THE FINAL VERSION OF THE FORM 990 FOR SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION REQUIRES DIRECTORS, OFFICERS, VOLUNTEER COMMITTEE MEMBERS, AND STAFF MEMBERS TO DISCLOSE REAL AND APPARENT CONFLICTS OF INTEREST FOR THEMSELVES AND THEIR FAMILY MEMBERS AND TO ANNUALLY SIGN A STATEMENT OF COMPLIANCE. AFTER A CONFLICT OR AN APPARENT CONFLICT OF INTEREST HAS BEEN DISCLOSED, THE BOARD OF DIRECTORS OR THE BOARD COMMITTEE, OR THEIR DESIGNEE, IN THE ABSENCE OF THE INTERESTED PERSON, SHALL DETERMINE IF THE CONFLICT OF INTEREST OR THE APPEARANCE OF A CONFLICT OF INTEREST EXISTS AND IS MATERIAL AND WILL DECIDE HOW IT IS TO BE MANAGED OR ELIMINATED. FORM 990, PART VI, SECTION B, LINE 15 BEGINNING IN 2015, THE NEWLY CREATED COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WILL REVIEW AND APPROVE THE SALARIES OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 ALL DOCUMENTS ARE AVAILABLE UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE. FORM 990, PART XII, LINE 2C: PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.